Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than general financial performance.
Material Changes
The filing reports a transaction on July 10, 2012, involving an increase in notional interests in Ordinary Shares for a connected person. This increase resulted from the notional re-investment of the dividend paid to shareholders on July 5, 2012, at a price of 1483 pence per Ordinary Share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of the participant's Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Key Facts for Investor Verification
- Transaction Date: July 10, 2012.
- Individuals Involved: Mr. P C Thomson (Director/PDMR) and Mrs. K Thomson (Connected Person).
- Transaction Details: Increase of 48.109 Ordinary Shares via notional dividend re-investment.
- Share Price: 1483 pence per Ordinary Share.
- Regulatory Basis: Notification made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).